Raymond James & Associates Has $9.17 Million Position in Encompass Health Co. (NYSE:EHC)

Raymond James & Associates decreased its holdings in shares of Encompass Health Co. (NYSE:EHC - Free Report) by 16.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 137,476 shares of the company's stock after selling 27,460 shares during the quarter. Raymond James & Associates owned about 0.14% of Encompass Health worth $9,172,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Vanguard Group Inc. lifted its holdings in shares of Encompass Health by 1.2% during the 3rd quarter. Vanguard Group Inc. now owns 9,653,180 shares of the company's stock valued at $436,613,000 after acquiring an additional 111,745 shares in the last quarter. William Blair Investment Management LLC lifted its holdings in Encompass Health by 6.4% in the 3rd quarter. William Blair Investment Management LLC now owns 5,676,379 shares of the company's stock worth $381,226,000 after buying an additional 342,512 shares in the last quarter. Invesco Ltd. lifted its holdings in Encompass Health by 22.3% in the 3rd quarter. Invesco Ltd. now owns 3,974,306 shares of the company's stock worth $266,914,000 after buying an additional 724,544 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Encompass Health by 4.4% in the 1st quarter. JPMorgan Chase & Co. now owns 3,144,147 shares of the company's stock worth $170,098,000 after buying an additional 133,885 shares in the last quarter. Finally, Baupost Group LLC MA lifted its holdings in Encompass Health by 318.9% in the 1st quarter. Baupost Group LLC MA now owns 3,000,000 shares of the company's stock worth $213,330,000 after buying an additional 2,283,900 shares in the last quarter. Institutional investors and hedge funds own 97.25% of the company's stock.

Encompass Health Stock Performance

Shares of NYSE:EHC traded up $2.36 during trading on Friday, reaching $83.36. 867,088 shares of the company's stock traded hands, compared to its average volume of 718,584. The company has a debt-to-equity ratio of 1.19, a current ratio of 1.28 and a quick ratio of 1.28. Encompass Health Co. has a 12 month low of $57.55 and a 12 month high of $83.73. The company has a 50 day moving average of $75.71 and a 200-day moving average of $69.47. The stock has a market capitalization of $8.35 billion, a P/E ratio of 24.02, a price-to-earnings-growth ratio of 1.54 and a beta of 0.94.

Encompass Health (NYSE:EHC - Get Free Report) last announced its quarterly earnings data on Wednesday, February 7th. The company reported $0.95 earnings per share for the quarter, beating analysts' consensus estimates of $0.83 by $0.12. Encompass Health had a net margin of 7.33% and a return on equity of 17.69%. The business had revenue of $1.25 billion during the quarter, compared to the consensus estimate of $1.24 billion. On average, equities analysts expect that Encompass Health Co. will post 3.96 EPS for the current year.

Encompass Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, April 15th. Shareholders of record on Monday, April 1st will be given a $0.15 dividend. This represents a $0.60 annualized dividend and a yield of 0.72%. The ex-dividend date is Thursday, March 28th. Encompass Health's dividend payout ratio (DPR) is 17.29%.

Analyst Upgrades and Downgrades

EHC has been the topic of a number of recent analyst reports. Stephens reiterated an "overweight" rating and issued a $85.00 price objective on shares of Encompass Health in a report on Tuesday, January 16th. Truist Financial boosted their target price on shares of Encompass Health from $82.00 to $86.00 and gave the stock a "buy" rating in a research report on Friday, February 9th. Mizuho boosted their target price on shares of Encompass Health from $77.00 to $82.00 and gave the stock a "buy" rating in a research report on Friday, February 9th. William Blair reissued an "outperform" rating on shares of Encompass Health in a research report on Wednesday, February 7th. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $83.00 target price on shares of Encompass Health in a research report on Friday, February 9th. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Encompass Health presently has an average rating of "Buy" and a consensus target price of $83.22.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.